8 Results for "

recurrent or metastatic

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "recurrent or metastatic" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-P99032
CAS No.: 1228763-95-8
Synonyms: IPH2201
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-109050
CAS No.: 1637771-14-2
Purity:  98.04%
Synonyms: GS-5829
Research Areas:  

Cancer

Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research .
loading...
    loading...
Cat. No.: HY-P99544
CAS No.: 2417649-97-7
Synonyms: HBM-9167; KL-A167

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .
loading...
    loading...
Cat. No.: HY-P99594
CAS No.: 2305043-30-3
Synonyms: ZKAB001; STI-1014; STI-A1014

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
loading...
    loading...
Cat. No.: HY-128938A
Purity:  98.04%
Target:  

ADC Linkers

Research Areas:  

Cancer

EC1167 hydrochloride is the linker for EC1169. EC1169 is prostate-specific membrane antigen targeting-tubulysin conjugate. EC1169 hydrochloride has the potential to treat recurrent metastatic, castration-resistant prostate cancer (MCRPC) .
loading...
    loading...
Cat. No.: HY-128938
CAS No.: 1610414-00-0
Target:  

ADC Linkers

Research Areas:  

Cancer

EC1167 is the linker for EC1169. EC1169 is prostate-specific membrane antigen targeting-tubulysin conjugate. EC1169 has the potential to treat recurrent metastatic, castration-resistant prostate cancer (MCRPC) .
loading...
    loading...
Cat. No.: HY-109050R
CAS No.: 1637771-14-2
Synonyms: GS-5829 (Standard)
Research Areas:  

Cancer

Alobresib (Standard) is the analytical standard of Alobresib (HY-109050). This product is intended for research and analytical applications. Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research .
loading...
    loading...
Cat. No.: HY-P992454

Target:  

Tim3

Research Areas:  

Cancer

S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1 antibody Sym021. S095018 also induces an increase in the density of CD8 + T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer .
loading...
    loading...